Supernus Pharmaceuticals | Les Charges D'Exploitation



Operating Expenses Changement Date
Abbott USD 9.06B 298M 2024-12
ANI Pharmaceuticals USD 194.95M 211M 2024-12
Aurora Cannabis CAD 51.98M 31.53M 2024-12
Bristol-Myers Squibb USD 11.55B 1.84B 2024-12
Canopy Growth CAD 98.58M 10.03M 2024-12
Corcept Therapeutics USD 156.63M 20.68M 2024-12
Eisai JPY 188.58B 7.01B 2024-12
Eli Lilly USD 8.38B 1.53B 2024-12
Indivior 303M 128M 2024-09
Novo Nordisk 37.49B 4.64B 2024-09
Pacira USD 162.55M 145.55M 2024-12
Perrigo USD 1.03B 13.4M 2024-12
Pfizer USD 18.17B 5.63B 2024-12
Supernus Pharmaceuticals USD 152.75M 17.91M 2024-12
United Therapeutics USD 378.2M 27.6M 2024-12
Xeris Pharmaceuticals USD 58.42M 8.74M 2024-12



Supernus Pharmaceuticals Les Charges D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Apr 2025.